Diabetes: Molecular Glues Protect Insulin Cells
- New York—Icahn School of Medicine at Mount Sinai researchers have found a potential way to protect insulin-producing beta cells from glucolipotoxicity, a condition accelerating type 2 diabetes (T2D).
- The research team's findings could lead to therapies that safeguard pancreatic cells, potentially delaying or preventing diabetes progression, reducing reliance on insulin, adn improving blood sugar control.
- The study identified small molecules, or "molecular glues," that enhance the interaction between ChREBPα and 14-3-3 proteins in pancreatic beta cells.
Groundbreaking research from Mount Sinai unveils a novel approach to safeguard insulin-producing beta cells. Discover how “molecular glues” are showing promise in the fight against type 2 diabetes. Scientists discovered that these molecules fine-tune ChREBP activity, vital for glucose metabolism, potentially preventing diabetes deterioration. This innovative method could revolutionize treatment by directly addressing beta cell loss, unlike current approaches.The small molecules enhance the interaction between ChREBPα adn 14-3-3 proteins, which prevents damage under glucolipotoxicity. This modulation plays a crucial role in preserving beta cell function. news Directory 3 is following this exciting advancement. Explore how this research may open doors to new therapeutic interventions and drug development in the realm of diabetes.Discover what’s next …
Mount Sinai Researchers Discover New Approach to Protecting Insulin-Producing Beta Cells
Updated june 18, 2025
New York—Icahn School of Medicine at Mount Sinai researchers have found a potential way to protect insulin-producing beta cells from glucolipotoxicity, a condition accelerating type 2 diabetes (T2D). The study, published in Nature Communications on March 2, 2025, suggests new treatments for beta cell dysfunction could be on the horizon. This research highlights the critical role of beta cell protection in managing diabetes.
The research team’s findings could lead to therapies that safeguard pancreatic cells, potentially delaying or preventing diabetes progression, reducing reliance on insulin, adn improving blood sugar control. This approach directly targets beta cell loss, unlike current treatments focused on managing blood sugar.
The study identified small molecules, or “molecular glues,” that enhance the interaction between ChREBPα and 14-3-3 proteins in pancreatic beta cells. ChREBP, a transcription factor, regulates glucose metabolism and exists in two forms: ChREBPα and ChREBPβ.
The molecular glues increase the binding between 14-3-3 proteins and ChREBPα, anchoring it in the beta cell’s cytoplasm. Under glucolipotoxicity, ChREBPα enters the nucleus and produces excess ChREBPβ, disabling and killing beta cells.The molecular glue prevents ChREBPα from entering the nucleus, thus halting ChREBPβ production. This modulation of protein interaction plays a crucial role in preserving beta cell function.
Testing on human beta cells showed that these molecular glues significantly reduced glucolipotoxicity’s toxic effects, preserving beta cell function. This discovery marks a shift in diabetes research, as transcription factors like ChREBP were previously considered “undruggable.” the study also underscores the potential of molecular glues for modulating similar interactions in other diseases, highlighting their versatile role in therapeutic interventions.
“This is an exciting step forward in our understanding of beta cell protection and the prevention of diabetes deterioration,” said Dr. Liora S.Katz,associate professor of medicine at the Icahn School of Medicine.”For the first time, we’ve shown that its possible to use small molecules to fine-tune carbohydrate response element binding protein (ChREBP) activity in a way that could have major therapeutic implications.”
“Our findings suggest a entirely new strategy for preserving beta cell function in diabetes,” said Dr. Donald K. Scott, professor of medicine at the Icahn School of Medicine. “This approach could complement existing diabetes treatments and help prevent disease progression.”
What’s next
Researchers are now refining these compounds and assessing their clinical potential. Future studies will focus on optimizing the molecular glues for therapeutic use and testing them in preclinical diabetes models.